Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting

Health and Human Services Department; Food and Drug Administration · 2011

Read Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-16234.txt.

Description

Notice published in the Federal Register on 2011-06-29 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 38188-38189] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-16234] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2011-N-0002] Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting AGENCY: Food and Drug Administration, HHS.

Catalog record

CREATORHealth and Human Services Department; Food and Drug Administration
YEAR2011
COLLECTIONLAW
FORMATTXT
FILE SIZE6 KB
VERSION1.0
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEFederal Register

Source: https://www.federalregister.gov/documents/2011/06/29/2011-16234/advisory-committee-for-pharmaceutical-science-and-clinical-pharmacology-notice-of-meeting

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting
Citation: us:fr:2011-16234
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/06/29/2011-16234/advisory-committee-for-pharmaceutical-science-and-clinical-pharmacology-notice-of-meeting
Context: Notice published in the Federal Register on 2011-06-29 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).

[Pages 38188-38189]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-16234]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]


Advisory Committee for Pharmaceutical Science and Clinical 
Pharmacology; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Advisory Committee for Pharmaceutical Science 
and Clinical Pharmacology.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on July 27, 2011, from 8 
a.m. to 5 p.m.
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 
31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 
20993-0002. Information regarding special accommodations due to a 
disability, visitor parking, and transportation may be accessed at: 
http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading 
``Resources for You'', click on ``Public Meetings at the FDA White Oak 
Campus''. Please note that visitors to the White Oak Campus must enter 
through Building 1.
    Contact Person: Yvette Waples, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
31, rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-
8533, e-mail: [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), and follow the prompts to the desired center or product area. 
Please call the Information Line for up-to-date information on this 
meeting. A notice in the Federal Register about last minute 
modifications that impact a previously announced advisory committee 
meeting cannot always be published quickly enough to provide timely 
notice. Therefore, you should always check the Agency's Web site and 
call the appropriate advisory committee hot line/phone line to learn 
about possible modifications before coming to the meeting.
    Agenda: On July 27, 2011, the committee will discuss current 
strategies for FDA's Office of Pharmaceutical Science implementation of 
quality by design principles within its review offices, incorporating 
an update on the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
Activities. The committee will also receive awareness presentations on 
FDA's current partnering with the United States Pharmacopeia, 
principally to discuss the Monograph Modernization Program.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before July 
20, 2011. Oral presentations from the public will be scheduled between 
approximately 10:45 a.m. to 11:15 a.m. and 3:30 p.m. to 4 p.m. Those 
individuals interested in making formal oral presentations should 
notify the contact person and submit a brief statement of the general 
nature of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an

[[Page 38189]]

indication of the approximate time requested to make their presentation 
on or before July 13, 2011. Time allotted for each presentation may be 
limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak by July 14, 
2011.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Yvette Waples at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 23, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-16234 Filed 6-28-11; 8:45 am]

Read the complete text